NCT04204278已完成不适用
A Prospective Study of a Single Injection Cross-linked Sodium Hyaluronate (MONOVISC) to Provide Symptomatic Relief of Osteoarthritis of Ankle Joint
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 4
- 主要终点
- Numerical Rating Scale (NRS) Pain on Walking
研究概览
简要总结
The goal of this study is to demonstrate the clinical improvement and safety in patients treated with MONOVISC for ankle osteoarthritis. Specifically, this study will provide confirmation to the effectiveness and safety of MONOVISC at relieving ankle joint pain to 6 months post-treatment.
详细描述
Obtain real world, post market data to confirm the clinical improvement and safety in patients treated with a single injection of MONOVISC for the symptomatic relief of osteoarthritis in the ankle joint. The entire study duration from first subject in to last subject out will be approximately one and half years. The enrollment phase will be approximately 12 months with a follow-up phase of 6 months. Visits will be scheduled at screening, baseline, 1 month, 3 months and 6 months post treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older
- •Body Mass Index (BMI) ≤ 35 kg/m2
- •Diagnosis of symptomatic osteoarthritic joint in the index joint (Kellgren-Lawrence grade I to III) to be treated with MONOVISC injection.
- •Failed conservative treatment for joint osteoarthritis.
- •NRS pain on walking ≥4 and ≤9 in the index joint.
- •Subject must be willing to abstain from other treatments of the index joint for the duration of the study.
- •Subject is willing to discontinue all analgesics including NSAIDs, except acetaminophen/paracetamol, at least seven days before the treatment injection and through the completion of the study.
- •Subject is willing to use only acetaminophen/paracetamol (up to a maximum of 4.0 grams per day per the package insert) for the treatment of joint pain for the duration of the study. At least forty-eight hours prior to the Baseline Visit and each follow-up visit, the subject is willing to discontinue use of acetaminophen/paracetamol.
- •Subject is willing to maintain a stable dose of oral glucosamine and/or chondroitin sulfate products throughout the study, if taken prior to signing the informed consent form (ICF).
- •Able and willing to provide signed informed consent.
排除标准
- •History of hypersensitivity to any of the ingredients in the hyaluronan
- •Infection or skin disease in the area of the injection site or index joint
- •NRS pain on walking > 3 in the contralateral joint
- •NRS pain on walking > 3 in the ipsilateral knee or hip
- •Subject received an injection of Hyaluronic Acid (HA) and/or steroid in either joint within 6 months of signing the informed consent form (ICF). A subject will be excluded if they are planning to receive an HA or steroid injection (other than the study injection) in either joint during the course of this study.
- •Known inflammatory or autoimmune disorders (including rheumatoid arthritis, gout), or other pre-existing medical conditions that, in the opinion of the investigator, could impact treatment of the index joint or affect the ability of the subject to accurately complete the study questionnaires and comply with the study requirements.
- •Subject is taking medications at the time of signing the ICF which could interfere with the treatment procedure, healing and/or assessments. This includes but is not limited to oral or injectable anticoagulant treatments, anti-aggregant platelet treatment, chronic opioid analgesics. Low dose aspirin used for cardiovascular protection is allowed if a stable regimen is maintained for the duration of the study.
- •Subjects who had an oral, intramuscular, intravenous, rectal suppository or topical (excluded in index joint only) corticosteroid prior 30 days of signing the ICF are excluded. Topical corticosteroid use at any site other than the index joint is allowed.
- •Significant trauma to the index ankle within 26 weeks of screening
- •Chronic use of narcotics or cannabis.
- •Ligament instability or tear in index joint.
- •Chronic impingement in the index joint requiring surgical treatment
- •Diagnosis of fibromyalgia
- •Diagnosis of osteonecrosis in index joint
- •Subject has significant varus or valgus deformity greater than 10 degrees in either knee.
- •Subject requires consistent use of an assistive device (e.g. wheelchair, walker, etc.) Occasional use of a cane is acceptable.
- •Uncontrolled diabetes with HbA1c of >7%.
- •Subject is a woman who is pregnant or breastfeeding at the Screening Visit or a woman of child bearing potential who refuses to use effective contraception during the course of the study.
- •Subject is receiving or in litigation for worker's compensation.
- •Otherwise determined by the investigator to be medically unsuitable for participation in this study.
结局指标
主要结局
Numerical Rating Scale (NRS) Pain on Walking
时间窗: Baseline to 6 Months
Mean Change in Numerical Rating Scale (NRS) Pain on Walking in the Index Ankle from baseline to 6 Months post injection. NRS is an 11-Point scale where 0=No Pain, 10=Worst Pain. A larger negative value (maximum -10.0) for the change from baseline indicates less pain and a better clinical outcome following treatment.
次要结局
- American Orthopaedic Foot and Ankle Society (AOFAS) Score(Baseline to 6 Months)
- Number of Participants NOT Using Rescue Medication (Acetaminophen/Paracetamol)(6 Months)
- Patient Global Assessment (PGA) Score(Baseline to 6 Months)
- The Outcomes Measures for Rheumatic Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Responder Index(6 Months)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
MONOVISC for Hip Joint Pain Relief Due to OsteoarthritisOsteoarthritis, HipNCT04204083Anika Therapeutics, Inc.25
已完成
不适用
MONOVISC for Shoulder Joint Pain Relief Due to OsteoarthritisOsteo Arthritis ShouldersNCT04204265Anika Therapeutics, Inc.25
已完成
不适用
Study of Cingal® for Symptomatic Relief of Osteoarthritis of Ankle JointOsteoarthritis, AnkleNCT04640974Anika Therapeutics, Inc.25
已完成
不适用
Study of Cingal® for Symptomatic Relief of Osteoarthritis of Hip JointOsteoarthritis, HipNCT04640298Anika Therapeutics, Inc.25
已完成
不适用
Study of Cingal® for Symptomatic Relief of Osteoarthritis of Shoulder JointOsteoarthritis, ShoulderNCT04640961Anika Therapeutics, Inc.25